XML 16 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Cash Flows From Operating Activities    
Net loss $ (10,401,863) $ (8,988,402)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 1,678,067 503,384
Bad debt expense 79,305 12,000
Gain on forgiveness of debt (24,925)  
Equity based compensation expense 3,543,887 2,646,013
Recognized loss on marketable securities 1,424 20,259
Expenses paid through financings   32,500
Loan principal paid directly through grant (2,992) (8,853)
Amortization of debt discount and debt costs 2,503,160 1,029,882
Warrant modification expense 12,624 0
Initial derivative expense 3,585,983 3,340,554
Change in derivative value due to anti-dilution adjustments 0 2,642,175
Change in fair value of derivative liability (7,315,580) (3,306,350)
Impairment expense 2,530,325 0
Change in fair value of earn-out liability 102,116 0
Changes in assets and liabilities:    
(Increase) decrease in accounts receivable (3,517,385) 126,492
Decrease in accounts receivable - related parties 15,043  
(Increase) decrease in prepaid expenses and other current assets (53,823) 25,950
Increase (decrease) in accounts payable and accrued liabilities 642,427 (68,633)
Decrease in accounts payable and accrued liabilities - related parties (687,460) 0
Decrease in deferred payroll taxes (135,699) 0
Increase in other liabilities (2,840) 132,950
(Decrease) increase in deferred revenue 456,824 (66,497)
Net cash used in operating activities (6,985,702) (1,926,576)
Cash Flows From Investing Activities:    
Proceeds from sale of marketable securities 0 17,009
Cash paid for customer contacts   (50,000)
Cash and receivables acquired 230,855 0
Cash paid for acquisitions (2,304,528) 0
Net cash used in investing activities (2,073,673) (32,991)
Cash Flows From Financing Activities:    
Proceeds from loans 250,000 398,545
Proceeds from convertible notes 2,153,200 2,226,000
Deferred offering costs (78,038)  
Repayments of notes (156,131) (11,155)
Advances on receivables 0 180,778
Repayments of advances on receivables 0 (180,778)
Repayments of sale of future revenues (10,904) (403,617)
Proceeds from sale of common stock 13,800,000 0
Offering costs (1,651,889)  
Proceeds from sale of preferred stock 0 25,000
Net cash provided by financing activities 14,306,238 2,234,773
Net increase in cash 5,246,863 275,206
Cash, beginning of period 99,906 306,252
Cash, end of period   581,458
Supplemental disclosures of cash flow information:    
Cash paid during the period for interest 175,580 128,979
Cash paid during the period for income taxes 0 0
Supplemental schedule of non-cash investing and financing activities:    
Original issue discount deducted from convertible note proceeds 342,554 328,125
Debt costs deducted from convertible note proceeds 334,800 366,500
Loans issued as consideration for acquisitions 4,750,000  
Notes and accrued interest converted to common stock 4,647,794 0
Common stock issued/to be issued for asset acquisitions 8,241,082 0
Notes payable and accrued interest exchanged for debentures 252,430 0
Accounts payable paid with common stock 140,000 0
Accrued compensation paid with common stock 16,425 0
Warrant derivative liability extinguished 10,182,476 0
Write off of right-of-use asset and lease liability 103,953 0
Earn-out liability consideration for acquisition 1,668,297 0
Shares issued for upsider earn-out liability 1,394,768 0
Deferred offering costs charged to additional paid-in capital 78,038 0
Preferred stock issued for accrued penalties 0 1,929,516
Warrant derivative liability at inception $ 2,374,076 $ 2,284,965